Company Information

  

Address: 10 POST OFFICE SQUARE
SUITE 502 SOUTH 
City: BOSTON 
State: MA 
Zip Code: 02109 
Telephone: 857-415-4774 

Description of Business

Primary SIC Code: 2834
(As filed with the SEC)  

We are a biopharmaceutical company focused on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and other liver or gastrointestinal, or GI, diseases and disorders. The initial target indication for our lead product candidate, A4250, is progressive familial intrahepatic cholestasis, or PFIC, a rare, life-threatening genetic disorder affecting young children for which there is currently no approved drug treatment. We have completed a Phase 2 clinical trial of A4250 in children with chronic cholestasis and pruritus and we plan to conduct a Phase 3 clinical trial in patients with PFIC. In addition to PFIC, we plan to consider conducting future clinical development of A4250 as a treatment for one or more other pediatric cholestatic liver diseases and disorders.  ... More ...  

Per Share Overview

Date 12-mos Rolling EPS Dividend P/E Ratio
03/2018-2.21NAN/E
12/2017-3.12NAN/E
09/20172.17NA9.65
06/2017-11.13NAN/E
03/2017-2.05NAN/E
12/2016-13.19NAN/E
09/2016-193.52NAN/E
06/2016-351.04NAN/E

Key Financial Ratios and Statistics

FYE: 12/31

Profitability 2017 Leverage 2017
Net Inc/Comm Equity-0.21Total Liab/Total Assets0.11
Net Inc/Total Assets-0.33Total Liab/Inv Cap0.12
Net Inc/Inv Cap-0.37Total Liab/Comm Equity0.07
Pretax Inc/Net Sales-24202.00Interest Coverage RatioNA
Net Inc/Net Sales-24414.00Curr Debt/EquityNA
Cash Flow/Net Sales-27566.00LTD/EquityNA
SG&A/NetSales11587.00Total Debt/EquityNA
Asset Utilization   Liquidity  
Net Receivables Turnover0.00Quick Ratio6.94
Inventory TurnoverNACurrent Ratio6.94
Inventory Day SalesNANet Rec/Curr Assets0.01
Net Sales/Work Cap0.00Inv/Curr AssetsNA
Net Sales/PP&E0.01  

Income Statement (Millions)

  3/31/2018 9/30/2017 6/30/2017 3/31/2017
Total Revenues(Net Sales) 11.20 0.00 0.00 0.00
Cost of Goods Sold NA NA NA NA
Selling & Admin Exps 5.63 3.31 3.65 3.29
Operating Income -0.58 -6.53 -6.61 -6.10
Interest Exp NA -0.40 0.40 NA
Pretax Income -1.62 -6.51 -6.18 -6.67
Other Income -0.02 0.00 0.59 -0.33
Net Income Bef Extraordinary ... NA NA NA NA
Net Income -1.62 -6.51 -6.18 -6.67

Balance Sheet (Millions)

Assets 3/31/2018 9/30/2017 6/30/2017 3/31/2017
Cash & Short Term Investments 192.92 57.07 62.60 20.14
Receivables - Total 1.44 0.74 0.66 0.64
Inventories - Total NA NA NA NA
Total Current Assets 195.02 58.14 63.73 21.34
Net Property, Plant & Equipment 0.17 0.19 0.16 0.11
Total Assets 212.90 77.09 82.68 40.30
Liabilities        
Accounts Payable 6.75 6.15 5.15 5.26
Debt in Current Liabilities NA 1.47 1.93 2.49
Total Current Liabilities 7.16 7.93 7.38 9.07
Long-Term Debt NA NA NA NA
Total Liabilities 52.73 7.97 7.42 9.10
Stockholder's Equity        
Minority Interest NA NA NA NA
Preferred Stock NA NA NA NA
Common Stock 0.12 0.09 0.09 0.06
Retained Earnings -51.98 -45.30 -38.79 -32.62
Treasury Stock NA NA NA NA
Total Stockholders' Equity 160.17 69.12 75.25 31.21
Total Liabilities and Stockholders' Equity 212.90 77.09 82.68 40.30

Cash Flow Summary (Millions)

Categories 3/31/2018 9/30/2017 6/30/2017 3/31/2017
Net Cash Provided by Operating Activities 1.10 -5.19 -5.90 -8.53
Net Cash Provided by Investing Activities -0.05 -0.04 -0.05 -0.10
Net Cash Provided by Financing Activities 138.68 -0.36 47.71 -0.79

Annual Summary Data (Millions)

Year Sales Net Income EPS
12/20150.00-18.74--
12/20155.10-6.77--
12/20160.00-13.76-13.19
12/201611.36-16.35-13.19
12/20170.00-24.41-3.12
Growth RatesInfinity----

Stock Ownership

Type Date(Q,M) No. Owners Shares Held (000s) % Own
Institutional06/30/18556,54454.81




Report Date : 7/16/2018

Powered By Edgar Online © 2018EDGAR®Online, a division of Donnelley Financial Solutions. EDGAR® is a federally registered trademark of the U.S. Securities and Exchange Commission. EDGAR Online is not affiliated with or approved by the U.S. Securities and Exchange Commission.